Innovation Ventures

Partnering Opportunities

• Neurodegenerative Diseases

  Restoring acid-β-glucosidase activity by non-inhibitory small molecule chaperones

  Restore GCase activity in the brain for Gaucher and Parkinson's

• Neurology

  Multi-Frequency Encoded Source Imaging

  A new imaging technology to localize and visualize electrical and/or magnetic signals in two or more frequency ranges.

• Neurology

  Small Molecule Inhibitors for Treating Demyelinating Diseases

  Small molecules, targeting HDAC3, enhance myelin repair in demyelinating diseases and injuries

• Pulmonology

  Serum Biomarkers and Algorithm of Lung Decline in Cystic Fibrosis

  Novel serum protein biomarkers and functional data analysis-based algorithm used to develop a predictive test for lung function decline.

• Infectious Disease

  Bivalent VLP Ebola Vaccine

  Bi-valent spherical virus like particle (VLP) vaccine against Ebola virus.

• Pulmonology

  Method of Treating Cystic Fibrosis with Src Kinase Inhibitors

  Scientists have shown that src kinase inhibitors are effective at treating CF patients with a frame deletion of F508 in the CFTR gene.

• Asthma

  Repurposing of Cysteamine for the Treatment of Asthma

  Cysteamine, an FDA approved treatment for cystinosis, has been shown to be an effective oral treatment for steroid resistant asthma including airway hyperresponsiveness (AHR) and airway inflammation.

• Metabolic disorder

  Autologous cell and gene therapy for Gaucher Disease

  Therapy for neuronopathic Gaucher Disease using gene therapy and a specialized neuronal lineage iPS cell that facilitates entry to and engraftment in the brain.

• Education & Learning

  Tracking Daily Preventive Activities of Infection-Prone Patients

  An electronic token economy module that tracks and encourages infection-prone patients to adhere to daily preventive activities.

• Oncology

  Inhibition of UBE2N as a Therapeutic Approach in MDS and AML

  Pharmacologic and genetic inhibition of UBE2N suppresses the function and viability of MDS/AML cells lines and patient samples. A commercially available compound has been identified.